Biostax Announces a Director Appointment of Influential Business Leader Craig Suro

Rhea-AI Summary

Biostax Corp (BTAX) announces the appointment of Influential Business Leader Roger “Craig” Suro, a renowned Virginia native with a track record in business innovation, public policy, and community revitalization. Mr. Suro's expertise in driving capital, innovation, and funding for transformative projects is expected to amplify Biostax's growth trajectory, bringing unparalleled opportunities and increased funding avenues.

Positive

• Appointment of Roger “Craig” Suro, a renowned business leader with a track record of driving capital, innovation, and funding for transformative projects, is expected to amplify Biostax's growth trajectory.
• Mr. Suro's extensive background in business development and public service is likely to bring unparalleled opportunities and increased funding avenues for Biostax.

Negative

• None.

Orlando, FL, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Influential Business Leader Roger “Craig” Suro.

Renowned Virginia native, Mr. Suro, has emerged as a driving force in the realms of business innovation, public policy, and community revitalization. With an extensive background in business development and public service, Mr. Suro has continually spearheaded transformative initiatives that have left a lasting impact on Virginia's economic landscape.

In welcoming Mr. Suro, the Company’s CEO, Noreen Griffin, remarked, "We are thrilled to have Craig join our team. His remarkable track record in driving capital, innovation, and funding for transformative projects is unparalleled. His expertise will undoubtedly amplify our company's growth trajectory. With Craig on board, we anticipate a surge in innovation, unparalleled opportunities for our company, and increased funding avenues that will propel us to new heights of success."

Mr. Suro's journey began as Virginia’s Assistant Secretary of Health and Human Resources under the office of Secretary Jane Woods where he exhibited exceptional leadership in policy coordination, legislative affairs, and relationship building with state healthcare agencies. His expertise in healthcare policies laid the foundation for his venture into the private sector, where he co-founded Caretime LLC in 2010. This private healthcare software company, under Mr. Suro's guidance, achieved remarkable success, experiencing an average annual revenue growth of 52%. Caretime's innovative solutions empowered healthcare providers across 26 states in detecting fraud within Medicaid- and Medicare-funded home healthcare services.

Recognized for his entrepreneurial acumen, Mr. Suro ventured into the aquaculture industry in 2014, founding the not-for profit, Tangier Island Oyster Company. His vision revitalized the economy of Tangier Island, providing over 1 million premium brand oysters annually to select restaurants creating a range of new employment opportunities and establishing a sustainable market for premium oysters.

In recent years, Mr. Suro's focus has shifted towards the burgeoning field of Biotechnology. Collaborating with leading companies in the Richmond/Petersburg region, he has been instrumental in driving innovative drug research and manufacturing projects. His consultancy work ensures that these initiatives maximize growth, fostering synergies that benefit communities, national safety, and public health.

Mr. Suro's dedication to community development is reflected in his service on several boards and committees. He serves on the Greater Richmond YMCA Board and currently volunteers on the Property and Facilities committee. Presently, he serves on the HCA Central Division Region Market Advisory Committee, the Community Board for Blue Ridge Bank, and the Board of Trustees for The Steward School.

With a legacy marked by innovation, collaboration, and community empowerment, Craig Suro continues to shape Virginia's future. His dynamic approach and visionary leadership make him a driving force behind transformative change, leaving an indelible mark on businesses, communities, and industries alike.

About Biostax
Biostax is an innovative biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology (MedTech) products with a well -defined path to market. We use a hub-and-spoke business model, where the parent company (hub) holds a centralized management and administrative team, and each subsidiary (spoke) operates a specialized development team focused on individual product pipelines.
Where Biostax has a diversity of product pipelines that will provide revenue while reducing risk, our goal is to develop new therapies that provide disease remission by restoring immune balance for patients with autoimmune, inflammatory, and infectious diseases without suppressing their immune system. Restoring homeostasis or balance to the immune system is the first step to a cure by improving patients’ lives in chronic illness caused by immune dysfunction and inflammation. www.biostaxcorp.com 

Forward Looking Statement
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions, and expectations of Immune’s future economic performance, considering the information currently available to it. These statements are not statements of historical fact. Although Immune believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Immune does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Immune will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause Immune’s actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory review and approval of our prospective products, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure, or prevent any disease.

Biostax Contact:
Noreen M. Griffin
Chief Executive Officer
ir@biostax.net

FAQ

Who is Roger “Craig” Suro?

Roger “Craig” Suro is an influential business leader with a track record in business innovation, public policy, and community revitalization.

What is Biostax Corp (BTAX)?

Biostax Corp (BTAX) is a hub and spoke biotech development engine.

What are Mr. Suro's accomplishments?

Mr. Suro has a remarkable track record in driving capital, innovation, and funding for transformative projects, as well as spearheading initiatives that have left a lasting impact on Virginia's economic landscape.

What is Mr. Suro's expertise?

Mr. Suro has expertise in business development, public service, and driving capital, innovation, and funding for transformative projects.

What is the impact of Mr. Suro's appointment on Biostax?

Mr. Suro's appointment is expected to bring unparalleled opportunities and increased funding avenues for Biostax, amplifying the company's growth trajectory.